Nanostructured Lipid Carriers of Eperisone Hydrochloride using Quality By Design Approach
Abstract
Objective: The current work involves formulation development of nanostructured lipid carrier (NLC) of eperisone hydrochloride (EPE) using quality by design (QbD) approach.
Materials and Methods: Initial screening of solid and liquid lipids was performed based on the Hansen solubility parameters of EPE and the lipids and later confirmed using saturation solubility studies. The optimum formulation was identified using three-squared randomized full factorial design. High shear homogenization coupled with ultrasonication was used to prepare the NLCs. The effect of the independent variables on the dependent variables was analyzed using response surface graphs and ANOVA. The optimized formulation is characterized for mean particle size, zeta potential, entrapment efficiency, in vitro drug release and subjected to stability testing.
Results and Discussion: Precirol® ATO 5, CapryolTM 90, and Pluronic® F127 are found to be ideal solid lipid, liquid lipid and surfactant respectively based on the initial screening. Amount of lipid mixture (X1) and the amount of surfactant (X2) were selected as independent variables and the entrapment efficiency (Y1), mean particle size (Y2) and zeta potential (Y3) were selected as dependent variables. The optimized NLC formulation has mean particle size of 175 nm, zeta potential -24.4 mV and entrapment efficiency of 78.64%. The in vitro drug release data suggested that the drug release follows Quasi-Fickian diffusion. The stability data showed that the NLCs are stable up to 3 months at refrigerated conditions.
Conclusions: The Hansen solubility parameter approach coupled with QbD is a powerful tool for formulation of sustained release NLCs of highly soluble poorly soluble drugs.
Keywords: Nanostructured lipid carrier, Solubility Parameters, Nanoparticles, Lipid based drug delivery, Quality by Design
Keywords:
Nanostructured lipid carrier, Solubility Parameters, Nanoparticles, Lipid based drug delivery, Quality by DesignDOI
https://doi.org/10.22270/jddt.v13i2.5938References
Akbari J, Saeedi M, Ahmadi F, Hashemi SMH, Babaei A, Yaddollahi S, et al. Solid lipid nanoparticles and nanostructured lipid carriers: A review of the methods of manufacture and routes of administration. Pharmaceutical Development and Technology. 2022:1-53. https://doi.org/10.1080/10837450.2022.2084554
Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nature reviews Drug discovery. 2014; 13(9):655-72. https://doi.org/10.1038/nrd4363
Kadam V, Bagde S, Karpe M, Kadam V. A comprehensive overview on biosimilars. Current Protein Peptide Science. 2016; 17(8):756-61. http://dx.doi.org/10.2174/1389203717666160226144618
Bheemidi VS, Tiruckovela M, Varanasi P. An imperative note on novel drug delivery systems. J Nanomed Nanotech. 2011; 2:100125. https://www.walshmedicalmedia.com/open-access/an-imperative-note-on-novel-drug-delivery-systems-2157-7439.1000125.pdf
Mamidi HK. Nano sponge as versatile carrie. Research Journal of Pharmaceutical Sciences. 2019;8(1):20-8. http://www.isca.in/IJPS/Archive/v8/i1/4.ISCA-RJPcS-2018-008.pdf
Kalepu S, Manthina M, Padavala V. Oral lipid-based drug delivery systems–an overview. Acta Pharmaceutica Sinica B. 2013; 3(6):361-72. http://dx.doi.org/10.1016/j.apsb.2013.10.001
Beloqui A, Solinís MÁ, Rodríguez-Gascón A, Almeida AJ, Préat V. Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomedicine: Nanotechnology, biology and medicine. 2016; 12(1):143-61. https://doi.org/10.1016/j.nano.2015.09.004
Kolimi P, Youssef AAA, Narala S, Nyavanandi D, Dudhipala N, Bandari S, et al. Development and characterization of itraconazole non-aqueous creams for the treatment of topical fungal infections. 2022:103818. https://doi.org/10.1016/j.jddst.2022.103818
Cabitza P, Randelli P. Efficacy and safety of eperisone in patients with low back pain: a double blind randomized study. Eur Rev Med Pharmacol Sci. 2008; 12(4):229-35. https://pubmed.ncbi.nlm.nih.gov/18727454/
Patel P, Patel M. Enhanced oral bioavailability of nintedanib esylate with nanostructured lipid carriers by lymphatic targeting: In vitro, cell line and in vivo evaluation. European Journal of Pharmaceutical Sciences. 2021; 159:105715. https://doi.org/10.1016/j.ejps.2021.105715
Shrivastava S, Gidwani B, Kaur CD. Development of mebendazole loaded nanostructured lipid carriers for lymphatic targeting: Optimization, characterization, in-vitro and in-vivo evaluation. Particulate Science Technology. 2021; 39(3):380-90. https://doi.org/10.1080/02726351.2020.1750515
Mamidi HK, Rohera BD. Application of thermodynamic phase diagrams and Gibbs free energy of mixing for screening of polymers for their use in amorphous solid dispersion formulation of a non-glass-forming drug. Journal of Pharmaceutical Sciences. 2021; 110(7):2703-17. https://doi.org/10.1016/j.xphs.2021.01.036
Mamidi HK. Preformulation Studies for the Preparation of Amorphous Solid Dispersions: St. John's University (New York); 2021. https://scholar.stjohns.edu/cgi/viewcontent.cgi?article=1324&context=theses_dissertations
Shah KA, Date AA, Joshi MD, Patravale VB. Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery. International journal of pharmaceutics. 2007; 345(1-2):163-71. https://doi.org/10.1016/j.ijpharm.2007.05.061
Garg NK, Sharma G, Singh B, Nirbhavane P, Tyagi RK, Shukla R, et al. Quality by Design (QbD)-enabled development of aceclofenac loaded-nano structured lipid carriers (NLCs): An improved dermatokinetic profile for inflammatory disorder (s). International Journal of pharmaceutics. 2017; 517(1-2):413-31. https://doi.org/10.1016/j.ijpharm.2016.12.010
Bolton S, Bor S. Pharmaceutical Statistics: Practical and Clinical Applications, Revised and Expanded: CRC press; 2003. https://doi.org/10.3109/9781420074239
Fang J-Y, Fang C-L, Liu C-H, Su Y-H. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). European Journal of Pharmaceutics and Biopharmaceutics. 2008; 70(2):633-40. https://doi.org/10.1016/j.ejpb.2008.05.008
Khairnar SV, Pagare P, Thakre A, Nambiar AR, Junnuthula V, Abraham MC, et al. Review on the Scale-Up Methods for the Preparation of Solid Lipid Nanoparticles. 2022; 14(9):1886. https://doi.org/10.3390/pharmaceutics14091886
Kumbhar M, Bagde S, Karpe M, Kadam V. HPLC method development and validation for estimation of eperisone hydrochloride from bulk and marketed formulation. International Journal of Pharmacy Research Technology. 2019; 9(1):6-14. https://www.ejmanager.com/mnstemps/17/17-1547992956.pdf?t=1666753524
Jannin V, Pochard E, Chambin O. Influence of poloxamers on the dissolution performance and stability of controlled-release formulations containing Precirol® ATO 5. International journal of pharmaceutics. 2006; 309(1-2):6-15. https://doi.org/10.1016/j.ijpharm.2005.10.042
Kolimi P, Narala S, Nyavanandi D, Youssef AAA, Dudhipala NJC. Innovative Treatment Strategies to Accelerate Wound Healing: Trajectory and Recent Advancements. 2022; 11(15):2439. https://doi.org/10.3390/cells11152439
Kothekar SC, Ware AM, Waghmare JT, Momin S. Comparative analysis of the properties of Tween‐20, Tween‐60, Tween‐80, Arlacel‐60, and Arlacel‐80. Journal of dispersion science and technology. 2007; 28(3):477-84. https://doi.org/10.1080/01932690601108045
Mamidi HK, Rohera BD. Material-Sparing Approach using Differential Scanning Calorimeter and Response Surface Methodology for Process Optimization of Hot-Melt Extrusion. Journal of Pharmaceutical Sciences. 2021; 110(12):3838-50. https://doi.org/10.1016/j.xphs.2021.08.031
Costa-Balogh FO, Sparr E, Sousa JJS, Pais AC. Drug release from lipid liquid crystalline phases: relation with phase behavior. Drug Development and Industrial Pharmacy. 2010; 36(4):470-81. https://doi.org/10.3109/03639040903261997
Mamidi HK, Srimathkandala MH, Sanka K, Ananthula MB, Bakshi V. Development and evaluation of nasal in situ gel formulations of alprazolam using in vitro and in vivo methods. International Journal of Pharmacy. 2015; 5(1):278-88. https://www.pharmascholars.com/articles/development-and-evaluation-of-nasal-in-situ-gel-formulations-of-alprazolam-using-in-vitro-and-in-vivo-methods.pdf
Published
Abstract Display: 610 
PDF Downloads: 500 PDF Downloads: 90 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.